Houston Wire & Cable Company (NASDAQ:HWCC) has gained 11.69% or $1.38 a share to settle at $13.19 with a volume of 77000 shares. For the past 52 weeks the stock has been trading between $8.64 and $14.66 with an average volume of 54,200 shares. Company has a market cap of $234 million and has 17.76 million in common outstanding shares.
Houston Wire & Cable Company is a distributor of specialty wire and cable and related services to the United States electrical distribution market. During the year ended December 31, 2009, the Company served approximately 3,000 customers in the United States.
Broadwind Energy (NASDAQ:BWEN) has gained 20.20% or $.29 a share to settle at $1.53 with a volume of 3 million shares traded. For the past 52 weeks, the stock has been trading between $1.21 a share and $4.80 a share with an average volume of 772,000 shares. Company has a market cap of $164 million and has 107 million in common outstanding shares.
Broadwind Energy Inc. (Broadwind) provides products and services to the United States wind energy industry. Its product and service portfolio provides its customers, including wind turbine manufacturers, wind farm developers and wind farm operators, with access to an array of wind component and service offerings. The Company also provides technical service and precision repair and engineering and specialized logistics to the wind industry in the United States.
Alnylam Pharma (NASDAQ:ALNY) has lost 1.97% or $.20 a share to settle at $9.94 with a volume of 104,000 shares, compared to its average three-month volume of 295,000 shares. For the past 52 weeks the stock has been trading between $8.79 and $18.85 a share with an average market cap of $420 million.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, the Company reported the positive results from the Phase II experimental RSV infection clinical trial, referred to as the GEMINI study.
ChipMOS Technologies (NASDAQ:IMOSD) has been relatively unchanged at $7.32 a share and an average volume of 65,244 shares. For the past 52 weeks the stock has been trading between $2.40 $8.45 with an average market cap of $202 million. Company has 27.63 million in common outstanding shares and trades with a beta of 2.48.
ChipMOS TECHNOLOGIES (Bermuda) LTD. (ChipMOS Bermuda) is a holding company. The Company provides a range of back-end testing services, including engineering testing, wafer probing and final testing of memory and logic/mixed-signal semiconductors. It also offers a selection of leadframe-based and organic substrate-based package assembly services for memory and logic/mixed-signal semiconductors.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has lost 2.26% or $.13 a share to settle at $5.61 with a volume of 209,000 shares. For the past 52 weeks the stock has been trading between four dollars and seven dollars a share with an average market cap of $185 million. It has 33 million in common outstanding shares and trades with a beta of 1.34.
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focused on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The Company's principal programs are directed towards supportive care, oncology and virology. In supportive care, the Company's first commercial product is RELISTOR (methylnaltrexone bromide) subcutaneous injection, a therapy for opioid-induced constipation (OIC) approved for sale in over 40 countries worldwide.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any current or recent stocks listed in this stock news report
